📚 Diabetes & Metabolism — L8: Dyslipidemia

📚 Lecture Overview

This lecture covers the pathophysiology, classification, diagnosis, and comprehensive management of dyslipidemia, with a specific focus on its relationship with diabetes mellitus and cardiovascular risk. Mastering this material is critical because dyslipidemia is a primary driver of atherosclerotic cardiovascular disease (ASCVD), a leading cause of morbidity and mortality in metabolic disorders.

🎯 Key Concepts & Definitions

• Dyslipidemia: A range of disorders including abnormally high or low lipoprotein levels, as well as structural disorders in lipid particle composition.
• Lipoproteins: Macromolecular complexes composed of a hydrophobic core surrounded by hydrophilic lipids and proteins, serving as transport vehicles for insoluble lipids.
• Apolipoproteins: Structural and functional proteins associated with lipoproteins that activate metabolism enzymes and act as receptor ligands.
• LDL-Cholesterol ("Bad Cholesterol"): The primary cholesterol-rich lipoprotein containing apo B-100 that plays a major causal role in atherosclerosis.
• HDL-Cholesterol ("Good Cholesterol"): The smallest lipoprotein responsible for reverse cholesterol transport, removing excess peripheral cholesterol and delivering it to the liver.
• Atherogenic Dyslipidemia in T2DM: A characteristic triad of increased triglycerides, elevated small dense LDL, and low HDL-C seen in insulin resistance.
• Primary Dyslipidemia: Genetic defects in lipid metabolism (e.g., Familial Hypercholesterolemia).
• Secondary Dyslipidemia: Acquired lipid abnormalities driven by conditions like type 2 diabetes, obesity, hypothyroidism, nephrotic syndrome, or specific medications.

📖 Main Content

Lipoprotein Structure and Metabolism

• Structure: Hydrophobic core (triglycerides and cholesteryl esters) surrounded by a surface coat of hydrophilic lipids (phospholipids and unesterified cholesterol) and apolipoproteins.
• Major Classes (ordered by relative density and size):
• Chylomicrons: Transport dietary triglycerides.
• VLDL (Very Low-Density Lipoproteins): Transport endogenous triglycerides from the liver.
• IDL (Intermediate-Density Lipoproteins): Precursors to LDL.
• LDL (Low-Density Lipoproteins): Major circulating cholesterol carrier, rich in apo B-100.
• HDL (High-Density Lipoproteins): Smallest particles responsible for reverse cholesterol transport.

Classification of Dyslipidemia

• Primary (Genetic) Dyslipidemia:
• Polygenic Hypercholesterolemia: Multiple gene defects, ↑↑ LDL, increased CVD risk.
• Familial Hypercholesterolemia (FH): Mutated or ↓ LDL receptor activity, ↑↑↑ LDL, extremely high premature CAD risk (Homozygous form manifests before puberty).
• Familial Hypertriglyceridemia: ↓ Lipoprotein lipase (LPL) activity, ↑↑↑ TG.
• Chylomicronemia: LPL or apo C-II deficiency, ↑↑↑ TG, presents with milky serum and pancreatitis (no increased ASCVD risk).
• Familial Combined Dyslipidemia: Overproduction of apo B, ↑↑↑ TG and ↑↑↑ LDL.
• Secondary Dyslipidemia:
• Driven by type 2 diabetes mellitus, obesity, metabolic syndrome, hypothyroidism, nephrotic syndrome, cholestatic liver disease, and medications (e.g., steroids, non-selective beta blockers, diuretics).

Diabetic Dyslipidemia (Atherogenic Lipid Triad)

• Driven by insulin resistance which causes:
• Decreased LPL activity (reduced catabolism of VLDL and chylomicrons).
• Increased release of free fatty acids from adipose tissue.
• Increased hepatic fatty acid synthesis and VLDL overproduction.
• Key Lipid Profile Changes in T2DM:
• Increased: Triglycerides, VLDL, small dense LDL-C, and Apo B-100.
• Decreased: HDL-C and Apo A.

Clinical Diagnosis and Examination

• History: Medications, family history of premature cardiovascular disease, diabetes, hypertension, and dyslipidemia.
• Physical Signs of Lipid Deposition (Xanthomata):
• Xanthelasma: Cholesterol deposits in eyelid skin (associated with LDL hypercholesterolemia).
• Planar Xanthoma: Yellow-orange deposits on interdigital skin or buttocks (Familial Hypercholesterolemia).
• Tendon Xanthoma: Deposits on extensor tendons (Achilles, hand, elbow) indicating severe LDL hypercholesterolemia.
• Juvenile Corneal Arcus (Arcus Lipoides): White/gray opaque ring at the corneal margin, highly unusual in children.
• Anthropometric Measures: Waist circumference (>94 cm in men, >80 cm in women) correlates with high cardiovascular risk.

Cardiovascular Risk Stratification

• Treatment strategy and target goals depend heavily on the baseline 10-year risk of fatal CVD (SCORE) or presence of established comorbidities:
• Very High Risk: Documented ASCVD, severe CKD (eGFR <30), calculated SCORE ≥10%, or FH with ASCVD/major risk factor.
• High Risk: Markedly elevated single risk factors (TC >310 or LDL-C >190 mg/dL, BP ≥180/110), moderate CKD (eGFR 30–59), calculated SCORE 5–<10%.
• Moderate Risk: Calculated SCORE 1–<5%.
• Low Risk: Calculated SCORE <1%.

Pharmacological and Lifestyle Management

• Therapeutic Lifestyle Change (TLC):
• Restrict saturated fat, cholesterol, and avoid trans fats entirely (artificial solid fats that raise LDL and lower HDL).
• Plant sterols and stanols: Compete with cholesterol for intestinal absorption, lowering total cholesterol and LDL-C.
• Physical Activity: Minimum 150 minutes/week of moderate-intensity aerobic exercise plus resistance training.
• Weight Loss: Aim for a 7% body weight reduction.
• Medical Treatment Lines:
  1. Statins (HMG-CoA reductase inhibitors):
  • Cornerstone therapy; inhibits cholesterol synthesis and lowers LDL-C.
  • Mandates statin use in all diabetic patients >40 years as primary prevention.
  • High-intensity statins: Atorvastatin 40–80 mg or Rosuvastatin 20–40 mg (aim for ≥50% LDL reduction).
  • Mnemonic for side effects: "My Heavy Diabetic Nerve Ache" (Myopathy, Hepatic toxicity, Diabetes risk, Neurological/memory issues, Allergic skin reactions). Most common side effect is myalgia linked to reduced Coenzyme Q10 synthesis.
    2. Ezetimibe: Inhibits intestinal cholesterol absorption; provides ~18% further LDL-C reduction when added to statins (dual inhibition).
    3. Bile Acid Sequestrants: Bind bile acids in the intestine, forcing fecal excretion and increasing hepatic cholesterol breakdown (e.g., Cholestyramine).
    4. Fibrates: Lower triglycerides by 20–50% and raise HDL-C by activating LPL via PPAR-alpha.
    5. Fish Oils / Icosapent Ethyl: Adjunctive agents used to lower high triglycerides (30–40% reduction).
    6. Emerging Therapies:
  • PCSK9 Inhibitors (Alirocumab, Evolocumab) and Inclisiran (siRNA): Maintain high LDL receptor expression by neutralizing PCSK9.
  • Bempedoic Acid: ACL inhibitor upstream of HMG-CoA reductase; useful in statin-intolerant patients (watch for hyperuricemia and tendon rupture risk).

📊 Visual Learning

💡 Important Points to Remember

• The Statin Rule: Statins are mandatory for all diabetic patients above 40 years of age as primary prevention regardless of baseline LDL.
• High-Intensity Dosing: Memorize high-intensity regimens: Atorvastatin 40–80 mg and Rosuvastatin 20–40 mg achieve a $≥ 50%$ drop in baseline LDL-C.
• Diabetic Lipid Triad: Insulin resistance causes high triglycerides, high small dense LDL, and low HDL-C.
• Chylomicronemia Caveat: Severe hypertriglyceridemia presenting with chylomicrons causes pancreatitis and milky serum, but paradoxically does not increase cardiovascular risk.
• Mechanism of Ezetimibe: It inhibits intestinal cholesterol absorption, serving as the primary add-on drug when statins alone fail to reach target LDL goals.
• Coenzyme Q10 Connection: Statin-induced myopathy is frequently associated with depleted intracellular CoQ10 synthesis.
• Bempedoic Acid Trap: It is an ATP citrate lyase inhibitor useful for statin-intolerant patients, but it can cause hyperuricemia and increased risk of tendon rupture.
• Reverse Cholesterol Transport: The core physiological role of HDL-C where excess peripheral cholesterol is swept away and delivered back to the liver.
• Trans Fats Danger: Artificially hydrogenated plant oils increase bad LDL while dropping good HDL; they should be completely avoided.

⚠️ Common Exam Questions

• The Statin Indication Trick: Examiners often present a 45-year-old patient with type 2 diabetes and normal lipid profiles and ask whether they need a statin. Trap: Students often think normal lipids mean no statin is needed. Correct Answer: Yes, ADA guidelines mandate statin therapy for all diabetic patients over 40 years old for primary prevention.
• Triglyceride Risk Confusion: Questions may ask which condition has the highest cardiovascular risk between familial hypercholesterolemia and chylomicronemia. Trap: Assuming all severe lipid elevations carry equal ASCVD risk. Correct Answer: Familial hypercholesterolemia carries a massive ASCVD risk, whereas chylomicronemia causes acute pancreatitis but does not increase cardiovascular risk.
• Statin Side Effect Distractors: MCQs will list various side effects of statins and mix up myopathy with liver enzyme changes. Remember that mild transient elevations in LFTs are possible, but true statin myopathy features marked CK elevation and muscle pain often exacerbated by concurrent fibrate use.

📝 Quick Review Checklist

I can define dyslipidemia in clinical practice and classify its primary vs secondary etiologies
I understand the core structural features and functions of lipoproteins and apolipoproteins
I can explain the mechanisms driving atherogenic dyslipidemia in type 2 diabetes mellitus
I know the clinical physical signs associated with severe lipid disorders (xanthomas, arcus lipoides)
I can state cardiovascular risk categories and matching target LDL and non-HDL goals
I know high-intensity statin dosages and their expected percentage reduction limits
I can list the key side effects of statins and their pharmacological management
I understand second-line and emerging drug classes (Ezetimibe, PCSK9 inhibitors, Bempedoic acid, Fibrates)